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Abstract
Background: Previous studies comparing quantitative proteomics and microarray data have
generally found poor correspondence between the two. We hypothesised that this might in part
be because the different assays were targeting different parts of the expressed genome and might
therefore be subjected to confounding effects from processes such as alternative splicing.
Results: Using a genome database as a platform for integration, we combined quantitative protein
mass spectrometry with Affymetrix Exon array data at the level of individual exons. We found
significantly higher degrees of correlation than have been previously observed (r = 0.808). The
study was performed using cell lines in equilibrium in order to reduce a major potential source of
biological variation, thus allowing the analysis to focus on the data integration methods in order to
establish their performance.
Conclusion: We conclude that part of the variation observed when integrating microarray and
proteomics data may occur as a consequence both of the data analysis and of the high granularity
to which studies have until recently been limited. The approach opens up the possibility for the first
time of considering combined microarray and proteomics datasets at the level of individual exons
and isoforms, important given the high proportion of alternative splicing observed in the human
genome.
Background
A number of studies have considered whether changes in
mRNA concentration are reflected by similar changes in
protein abundance e.g. [1-4]. Typically, poor correspond-
ence has been reported between transcript and protein
levels, and in some cases, little or no correlation at all e.g.
[4]. Given the complexities of protein expression, and the
many stages at which it may be influenced and/or actively
controlled, this is perhaps to be expected.
Analogies can be drawn with studies that aim to compare
microarray data generated using different platforms.
These have highlighted the importance of filtering to
remove data with poor signal to noise ratio, and the need
to restrict comparisons to those pairs of reporters that tar-
get the same transcript location [5-7]. Transcript location
is particularly important because approximately 50% of
all human genes are predicted to be alternately spliced
[5,8]. In many cases, different exons from the same gene
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cell at different abundances. Most microarrays (e.g. the
HGU133plus2 array from Affymetrix) typically offer only
a single reporter per gene, and target locations differ
between platforms. Cross mappings have generally been
performed simply by seeking reporters annotated to the
same gene identifier. The alternative, of restricting analy-
ses only to those reporter-pairs that target the same tran-
script location, results in a significant proportion of the
data being lost. A new generation of arrays have been
developed with sufficient feature density to target every
known and predicted exon in the human, mouse or rat
genomes [5]. These 'exon' arrays offer a choice of probeset
location when performing comparative studies, and allow
cross-mapping to be performed with high precision, while
still preserving much of the gene-level array data [5].
Numerous studies have also observed that differences in,
for example, sample preparation, hybridization condi-
tions and binding affinities can all have a significant influ-
ence on measured expression level. This makes direct
comparisons between raw intensities challenging,
although good correspondence is reported when compar-
isons are made using ratio data, e.g. [6].
We investigated whether similar considerations could be
applied to quantitative mass spectrometry proteomics
data generated using the iTRAQ reagent system [9]. iTRAQ
(isobaric Tags for Relative and Absolute Quantitation,
Applied Biosystems, ABI) is an extension of other
approaches to protein identification (reviewed in [10]), in
which a protein sample is fragmented and then separated
into distinct peptides by liquid chromatography (LC).
Peptides are then analysed using mass spectrometry to fur-
ther fragment them and measure the mass to charge ratio
for each resultant ion. In silico comparison of the resulting
ion signature against a database generated from known
protein sequences is then used to identify each peptide,
and thus their originating proteins.
iTRAQ, like other similar approaches such as iCAT and
SILAC [4], adds an additional labelling step following the
initial fragmentation in which a chemical tag is attached
to each peptide. The aim is to label every peptide in an
experimental sample with a molecule of known mass
(referred to here as 'the reporter group') and use the rela-
tive abundance of these reporter groups to determine the
relative abundance of each peptide across samples. The
mass spectrometry system is set up such that each
(labelled) peptide is analysed separately. Multiple sam-
ples are compared in a single MS run, each labelled with a
different sized reporter group. In addition, each tag con-
tains a balance group, designed such that the labels used
for each sample have the same overall mass. This has the
consequence that all instances of a given peptide are proc-
essed at the same time by the mass spectrometer, irrespec-
tive of the experimental sample from which they
originated, and has been shown to lead to improved accu-
racy [11,12]. When the labelled peptide is processed in the
mass spectrometer it fragments, resulting in a series of
ions corresponding to the fragmented peptide (which are
used for identification in the usual way) and an additional
set of peaks corresponding to the reporter tags for each
sample. By determining the relative intensities of these
reporter peaks, the relative abundance of a given peptide
can be compared between samples.
Since the major focus of this paper is to consider whether
the increased precision offered by exon arrays can be used
in combination with proteomics data in order to improve
the quality of the mappings between the two data sources,
a biological system was chosen in which relatively high
correlation between protein and transcript data might be
expected, thus making it possible to establish a baseline
level of correlation in a well-controlled system. In previ-
ous work using cell-lines in equilibrium, for example [2],
relatively high correspondence (r = 0.59) has been
reported. Here, two cell lines in steady state were also cho-
sen. They provide not only a ready source of high quality
RNA and protein (thus minimizing a significant source of
technical variation), but also a system in dynamic equilib-
rium in which a major source of biological variation is
removed. The aim was to generate a well-controlled data-
set with which to investigate and evaluate different data-
integration approaches.
Results
Protein and mRNA samples were extracted from the
human breast cancer cell line MCF7, and MCF10A, a non-
tumourigenic human breast epithelial cell line. Material
was processed according to manufacturers' recommenda-
tions (full protocols are available in the supplementary
data). These cell lines have been used repeatedly in a vari-
ety of validation studies, e.g. [5,13-15], and the microar-
ray data have been previously validated using real time
PCR and by comparison between array types [5,13].
Microarray data were pre-processed using RMA [16] in
BioConductor [17]; proteomics data using ProteinPilot
and ProGroup (Applied Biosystems, Warrington, UK).
In this section, mappings between the proteomics data
and HGU133plus2 arrays and mappings between the pro-
teomics data and Exon arrays are both considered. An
overview of the approaches is shown in Figure 1.
Transcript to protein comparison (plus2 arrays)
In order to compare the method against current
approaches, we first analysed the proteomics data along-
side microarray data produced by hybridizing the RNA to
HGU133plus2 arrays (Affymetrix, High Wycombe, UK).
Protein level summaries were generated using ProteinPi-Page 2 of 11
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(Applied Biosystems, Warrington, UK). SWISS PROT
identifiers, provided as part of the database annotation,
were mapped to the array data using GeneCruiser [18].
643 proteins were identified in this search (555 after filter-
ing to remove low-quality data). 341 proteins were not
mapped, either because they did not have an associated
identifier (284/555 were found) or because no matching
probeset was found (214/284 were found). In total, 214
proteins were mapped to 353 probesets, via 276 genes;
figure 2. For these data, r = 0.715, p value of significance
< 1 × 10-16. Similar results were observed when mapping
via Genbank [19] accession and by searching other pro-
tein databases (data not shown).
Schematic of mapping strategiesFigure 1
Schematic of mapping strategies. (1) Conventional approach. A summary value for each protein is mapped to its cor-
responding plus2 array probeset via SWISS-PROT sequence identifiers. (2–4) Mappings performed via the genome. (A) 
Exon array and plus2 array probesets are associated with their target exons using the X:Map database. These are then mapped 
to genomic coordinates via X:Map and Ensembl. (B) Peptide sequences are mapped to proteins using a sequence search against 
the Ensembl protein database and then mapped to genomic coordinates using the Ensembl Perl API. (2) Exon array compar-
ison. Individual peptides are mapped to exons and then to their corresponding exon array probeset. (3) Plus2 array com-
parison. Individual peptides are mapped to exons and then to array probesets, as before. Since the majority of transcripts on a 
plus2 array are represented only by a single probeset placed at the 3' end of the transcript, many peptides cannot be mapped to 
an appropriate probeset. (4) Exon array mappings. A summary fold-change is created for the proteomics and microarray 
data by averaging across the peptides or probesets, respectively. These are then mapped via the genome to produce a compar-
ison between transcript and protein level summaries.Page 3 of 11
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which a single reporter (probeset) is used for the majority
of transcripts, peptide data are summarised to provide a
single value per protein, and mappings between the pro-
tein and the transcript data performed at the level of indi-
vidual transcripts and proteins.
In order to investigate whether exon arrays could be used
to enhance the quality of an integrated mRNA/proteomics
analysis, a separate array study in which the same RNA
was hybridized to Affymetrix Exon 1.0ST GeneChip®
(Affymetrix, High Wycombe, UK) arrays was also consid-
ered. Data were pre-processed using RMA, as before. High
correspondence between these arrays and the
HGU133plus2 arrays described above has been previ-
ously reported, demonstrating the intrinsic compatibility
of both sets of array data [5].
Probeset to peptide comparison (exon arrays)
Since exon arrays aim to provide a probeset in every
known and predicted exon in the entire genome, they
raise the possibility of performing a much more fine
grained analysis than has been previously possible. This
might be done by mapping individual peptides to the
High correspondence between plus2 array and quantitative proteomics dataFi ure 2
High correspondence between plus2 array and quantitative proteomics data. Each point corresponds to a matched 
transcript-protein pair using GeneCruiser annotation. X and Y axes: fold-changes between MCF7 and MCF10A for the micro-
array data and the quantitative proteomics data, respectively. When more than one matching probeset was found, the mean 
value was calculated, protein level averages were calculated by ProGroup. r: Pearson correlation. n: number of data points. No 
error bars are shown since these data are not provided by ProGroup.Page 4 of 11
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database to assign peptides to their originating exons,
rather than by simply performing transcript and protein
level summaries and mapping based on sequence id. To
investigate this, a peptide-level analysis was conducted. A
sequence search, combined with Ensembl [20], was first
used to position peptides within their candidate proteins,
after which they were aligned relative to the genome, and
mapped to their originating exons using X:Map and exon-
map [8]. X:Map and exonmap were then used to provided
mappings to the exon array probesets. A peptide and
probeset where mapped if they were found to originate
from (or target) the same exon.
Another source of error in microarray studies arises
because certain probes can hybridize to multiple targets
[21]. An analogous situation can occur with peptides that
match multiple places within the proteome. Data were
thus filtered to remove probesets and peptides that may
have originated from multiple locations in the genome
[8]. From an initial set of 2,118 peptides, 1,934 remained
after filtering for poor signal to noise ratio, and 1,168 after
filtering for non-specificity. All peptides mapped to at
least one exon, yielding 1,108 individual exons from 452
unique genes. When array mappings were performed, 856
of these exons mapped to 1,566 probesets, 1,094 of which
were found by X:Map to target only a single location in the
genome. Fold changes were computed for the remaining
microarray and proteomics data, and their Pearson corre-
lation found: r = 0.808 p < 1 × 10-16 ; figure 3. The differ-
ence in r (between figures 2 and 3) was also found to be
statistically significant: p = 0.004, suggesting that exon
arrays not only support mappings at the level of individ-
ual peptides but also lead to a marginal increase in the
overall correspondence in the integrated dataset. Where
multiple probesets (often corresponding to multiple start
or end point predictions), and/or multiple peptides, are
mapped to the same exon, these were averaged (error bars
represent 1SD in these averaged values).
Probeset to peptide comparison (plus2 arrays)
A similar analysis was performed using the HGU133plus2
data. Probesets were mapped if they matched the genome
within 1,000 nucleotides up- or downstream of a peptide.
Using this, less stringent mapping, only 161 peptides were
successfully mapped to a corresponding HGU133plus2
probeset r = 0.792; p < 1 × 10-16; figure 4. An exon level
mapping, as before, yielded only 91 successful peptide-
matches, and as the size of the margin for an acceptable
match increases, r decreases as expected (data not shown).
These results demonstrate that although the approach is
successful with plus2 array data it is only practical with
high coverage arrays such as the Exon 1.0ST array; the rel-
ative paucity of probesets on the plus2 arrays means that
very few are co-localized with a peptide, with the result
that the majority of peptides are lost from the analysis.
Transcript to protein comparison (exon arrays)
We also considered the suitability of protein level summa-
ries generated by averaging the individual fold-changes
for all peptides matching to a given protein, as is com-
monly used to represent protein expression. We compared
these values to their corresponding transcript level aver-
ages produced from the exon array data (figure 5; r =
0.792; p < 1 × 10-16). Although figure 5 shows high corre-
lation between protein and transcript, many of the meas-
urements also show high variance (the error bars in figure
4 represent 1 SD away from the mean). This is unlikely to
be due simply to noise or technical artefacts, since there is
highly significant correlation between individual probeset
and peptide measurements, confirming their reliability
(figure 3).
It is likely therefore, that much of this variation is a conse-
quence of real biological events, such as alternative splic-
ing. It is thus difficult to find a meaningful biological
interpretation for protein or transcript level averages,
since they mask a significant amount of underlying infor-
mation that cannot be adequately represented as a single
number. They should therefore be interpreted with care,
even though correlation between them is high.
Discussion
One of the major aims of this study was to perform a tech-
nically replicated experiment in which many sources of
biological variation were controlled and thus to establish
a baseline level of correlation between proteomics and
microarray data. Thus the comparison was between two
cell lines, allowing significant quantities of high quality
RNA and protein to be produced, and, since each cell line
was in a steady state, a major source of biological variation
to be controlled [2,22]. This strategy is reflected in the
high correspondence seen, not only in the HGU133plus2,
but also the exon array comparisons, and is also a reflec-
tion of the quality of the data produced by both the
iTRAQ and the Affymetrix systems. As mentioned in the
introduction, previous work with steady state cell line
data[2], has also reported substantial, albeit lower, corre-
lation (r = 0.59), using different technology (ICAT and
Agilent 60 mer arrays). Here we find significantly higher
correlation (r = 0.808; difference in r; p = 9 × 10-14).
Clearly, these results should be interpreted with some cau-
tion given the differences between the two studies, which
include differences in the platforms used to perform the
assays, the informatics approaches used to integrate the
data and the biological system under investigation. How-
ever, the data presented here do show that high correla-
tion between proteomics and microarray data can be
observed in steady state cell line data.Page 5 of 11
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first time that it is feasible to use individual peptide ratios
and compare them successfully to their corresponding
exon array probeset by mapping via a genome annotation
database. This is particularly important given the fact that
at least half of the human genome is alternatively spliced.
The substantial correlation found at the peptide-exon
level, the high degree of variation observed within each
individual data point at the transcript-protein level and
the large amount of alternate splicing known to occur in
the genome, together raise some substantial questions
about the validity of averaged protein or transcript level
summaries taken across the length of a 'gene'.
A criticism that can be made of quantitative proteomics
approaches is that, in contrast to transcriptomics, it is not
possible with current technology to fully characterize the
entire proteome in a complex organism such as homo sapi-
ens. However, the field is undergoing rapid development
and it is likely that these issues will continue to be
resolved as the technology progresses. The strategy
described here relies on mapping reporters from the dif-
ferent platforms (i.e. peptides and microarray probesets)
to one another via the genome. The approach is, therefore,
relatively generic, and could equally be applied to other
quantitative techniques.
High correspondence between exon array and quantitative peptide dataFi ure 3
High correspondence between exon array and quantitative peptide data. Each point corresponds to an exon 
matched by at least one peptide and at least one array probeset. X and Y axes: fold-changes between MCF7 and MCF10A for 
the microarray probeset and quantitative peptide data, respectively. When more than one matching peptide/probeset was 
found, the mean value was calculated. Error bars represent one standard deviation. r: Pearson correlation. n: number of data 
points.Page 6 of 11
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These findings suggest that much of the variation found
between proteomics and microarray data occurs at least in
part as a consequence of the data analysis techniques and
the high granularity to which such studies have, until
recently, been limited. When data processing takes into
account the importance of alternative splicing, probeset
location, issues of peptide/probeset selectivity and signal
to noise ratio, a surprising degree of correlation is
observed in the data. Where differences do remain, these
are more likely to represent biological rather than techni-
cal effects, thus enhancing our ability to identify and pur-
sue genes for which protein expression is modulated post-
transcription.
Methods
Cell culture
MCF7 cells were grown in Dulbecco's modified Eagle's
medium (DMEM) with 10% (v/v) fetal calf serum (FCS;
Invitrogen, Carlsbad, CA, USA), and MCF10A was grown
High correspondence between plus2 array and quantitative proteomics data mapped by peptide proximityFi ure 4
High correspondence between plus2 array and quantitative proteomics data mapped by peptide proximity. 
Each point corresponds to a matched probeset-peptide pair. A mapping was made when the genomic-origin of a peptide was 
within 1000 base pairs of the genome location of a microarray probeset. X and Y axes: fold-changes between MCF7 and 
MCF10A for the microarray data and the quantitative proteomics data, respectively. When more than one matching probeset 
was found for a given peptide, the mean value was calculated. r: Pearson correlation. n: number of data points. No error bars 
are shown because no averaging was performed because mapping was based on probeset/peptide location, rather than higher 
level features such as transcripts or exons, which provide a rationale strategy for grouping the peptides/probesets.Page 7 of 11
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Paisley, UK), 2 ng/mL epidermal growth factor (Pepro-
Tech, Rocky Hill, NJ, USA), 0.5 μg/mL hydrocortisone, 0.5
μg/mL cholera toxin, and 5 μg/mL insulin (Sigma, St.
Louis, MO, USA). Protein content per cell was similar for
the two populations and all experiments were performed
on sub-confluent cells cultured at the same density.
Microarray processing
All experiments were performed using either Affymetrix
HGU133 plus 2.0 or Exon 1.0ST arrays (Affymetrix, High
Wycombe, UK). A complete description of procedures is
available at [23].
• HGU133plus2 arrays
 GeneChip_Target_Prep_Protocol-CR-UK_v2.pdf
• Exon1.0ST arrays
 _HYBRIDISATION_PROTOCOLS/Exon 1.0 ST Hybridi-
sation v1.0.pdf
Three technical replicates were performed for each micro-
array experiment.
High correspondence between protein and transcript level summary averages in exon array dataFi ure 5
High correspondence between protein and transcript level summary averages in exon array data. Each point 
corresponds to a transcript matched by at least one peptide and at least one array probeset. X and Y axes: fold-changes 
between MCF7 and MCF10A for the microarray-probeset and quantitative-peptide data, respectively. When more than one 
matching peptide/probeset was found, the mean value was calculated. Error bars represent one standard deviation. r: Pearson 
correlation. n: number of data points.Page 8 of 11
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Flow diagram showing the different steps required for the integration of iTRAQ and Exon 1.0ST dataigure 6
Flow diagram showing the different steps required for the integration of iTRAQ and Exon 1.0ST data. MCF7 & 
MCF10A cell lines were used as a source for protein and mRNA material. (LC) Liquid Chromatography; (MS/MS) Tandem Mass 
Spectrometry; (RMA) Robust Multichip Average.
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Two million cells were washed with PBS, centrifuged at
500 × g for 5 minutes and the dried pellet lysed in 0.5 M
triethylammonium bicarbonate + 0.05% (w/v) SDS. Pro-
tein was digested and iTRAQ labelled as described previ-
ously[24]. Briefly, 100 μg protein in 20 μl was reduced
with 2 μl 50 mM tris-(2-carboxyethyl)-phosphine (TCEP)
at 60°C for one hour and then alkylated with 1 μl of 200
mM methylmethanethiosulphate (MMTS) in isopropanol
at room temperature for 10 minutes. Protein was digested
by addition of 10 μl of trypsin at 0.5 μg/μl and incubated
at 37°C overnight. One unit of iTRAQ reagent (Applied
Biosystems, Warrington, UK), was thawed and reconsti-
tuted in 70 μl of ethanol, with vortexing for 1 minute. The
reagent solution was added to the digest and incubated at
room temperature for one hour. Labeling reactions were
then pooled prior to analysis. Two technical replicates
were performed. MCF7 cells were labelled with 114 and
116 reporter ions, MCF10A with 115 and 117.
Liquid Chromatography and Mass Spectrometry
Pooled labelled peptides were analysed as previously
described[24]. Briefly, peptides were fractionated on an
SCX cartridge (Applied Biosystems) in 10 mM K2HPO4
(pH 2.7) + 20% ACN, with KCl concentration increasing
in 50 mM steps from 50 mM to 500 mM. Peptide fractions
were dried, and re-suspended in 240 μL 2% v/v ACN/
0.1% v/v formic acid. 60 μL was loaded onto a 15 cm
reverse phase C18 column (75 μm i.d.) using an LC Pack-
ings UltiMate™ pump and peptides separated on a 80 min
gradient from 5% to 40% v/v ACN/0.1% v/v formic acid
on-line to a QSTAR® XL mass spectrometer.
Data analysis
Relative Quantification and Peptide assignments
iTRAQ data analysis and peptide/protein database searches
were performed using the ProteinPilotTM software (version
1.0, Applied Biosystems, Warrington, UK,). The uninter-
preted spectra were searched against the human Celera pro-
tein database: human_KBMS5.0.20050302.fasta (187,748
proteins). Only peptide matches with a confidence >= 95%
were considered. The program was configured to report
methylmethanethiosulfate (MMTS) as a fixed modifica-
tion.
Microarray Data analysis
All analyses were performed using BioConductor/R[17].
Raw expression data were processed in R using the affy
BioConductor libraries. Expression summarization was
performed using RMA[16,25] with chip definitions sup-
plied via a custom CDF file as described in[5]. Probeset to
genome mappings were performed using exonmap[8].
Peptide mappings
An overview of the data analysis strategy used to integrate
the exon array and proteomics data is presented in figure
5. The set of distinct peptides reported by ProteinPilot
(Applied Biosystems, Warrington, UK) following data-
base search was extracted from the output file and filtered
to retain only those peptides with >95% confidence, a
contribution > 0 to the final protein identification, and
flagged by ProteinPilot as being used for quantification).
Then, the list was locally BLAST [26] searched (-M PAM30
-e 100 -W 2) against the human Ensembl [20] peptide
database (Homo_sapiens.NCBI36.42.pep.all.fa), in order
to retrieve Ensembl transcript IDs. This approach indi-
rectly compares the Celera and the Ensembl databases.
Minor discrepancies between the two databases therefore
resulted in a small number of peptides not being mapped.
The high e-value set for the BLAST search ensured that
almost all possible hits were obtained. Nevertheless, only
the exact peptide matches (i.e. 100% identity) of the same
length as the query length were extracted. Finally, a BioP-
erl Ensembl API script [27] was used to pull out the pep-
tides genomic coordinates. For peptides located within
exon-exon junctions, two sets of coordinates were
retrieved. Similarly, a peptide sequence that exists in more
than one place in the genome (e.g. shared between pro-
tein families), would also have more than one set of coor-
dinates. These 'multi-target' peptides were excluded from
further analysis.
For comparisons involving the Exon1.0ST array data, pep-
tides were mapped by location, using X:Map, to their 'par-
ent' exons (figure 2) and transcripts (figure 4). Exonmap
was then used to map these exons/transcripts to their cor-
responding probesets. Probesets that were found by
X:Map to contain one or more probes capable of hybrid-
izing to the genome at multiple locations were removed
by filtering.
For peptide level comparisons involving the
HGU133plus2 array data, plus2 probeset locations were
found using ADAPT [28]. Peptides were mapped to a
probeset either via exon, as before, or when one was
found within 1000 residues of the peptide location.
Protein to HGU133 plus2 comparisons
ProteinPilot was used to generate summaries, as before.
These were then processed using ProGroup (Applied Bio-
systems, Warrington, UK) to generate protein level sum-
maries. SWISS PROT identifiers, which form part of the
Celera database annotation, were then mapped to
probeset IDs using GeneCruiser [18].
Correlation calculations
Pearson correlation was calculated as implemented by the
'cor' function in R and significance tested using t = r *Page 10 of 11
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and r is the correlation between them [29]. Significance of
comparison between correlation coefficients was calcu-
lated using Fisher's transformation to z-scores. For exon
level comparisons (figure 2), each data point corresponds
to a peptide and probeset mapping to the same exon, and
correlation calculated between the log2 fold changes
reported for the peptides and probesets. Where multiple
peptides or probesets mapped to the same exon, correla-
tion was calculated using the mean peptide or probeset
value for that exon. For these, error bars in the figure indi-
cate one standard deviation away from the mean.
For transcript and protein level summaries using the exon
array data (figure 4), the correlation is calculated between
the mean log2 fold change for all exon targeting probesets
and all peptides. As before, error bars in the figure indicate
one standard deviation away from the mean.
For transcript and protein level summaries using the
HGU133plus2 arrays, the correlation is calculated
between the log2 fold change for the array probeset and
the corresponding protein level average across peptides,
determined using ProGroup, as described above.
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